WO2023069028A1 - A process for the preparation of dry powder compositions for inhalation - Google Patents

A process for the preparation of dry powder compositions for inhalation Download PDF

Info

Publication number
WO2023069028A1
WO2023069028A1 PCT/TR2021/051073 TR2021051073W WO2023069028A1 WO 2023069028 A1 WO2023069028 A1 WO 2023069028A1 TR 2021051073 W TR2021051073 W TR 2021051073W WO 2023069028 A1 WO2023069028 A1 WO 2023069028A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
carrier
rpm
acid
sodium
Prior art date
Application number
PCT/TR2021/051073
Other languages
French (fr)
Inventor
Turgay KACAR
Ali Ihsan SECKIN
Emine Yilmaz
Devrim Celik
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to PCT/TR2021/051073 priority Critical patent/WO2023069028A1/en
Publication of WO2023069028A1 publication Critical patent/WO2023069028A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • the invention relates to a simple, rapid, cost-effective, time-saving and industrially convenient process for the preparation of dry powder pharmaceutical compositions comprising leukotriene receptor antagonist as active agent. Further, the present invention also relates to the dry powder pharmaceutical compositions administered by means of inhaler devices comprising leukotriene receptor antagonists and at least one pharmaceutically acceptable excipient.
  • leukotriene receptor antagonists The main indication for leukotriene receptor antagonists is in the treatment of chronic asthma and allergic rhinitis.
  • Leukotrienes are synthesized from arachidonic acid by the action of 5- lipoxygenase in many inflammatory cells in the airways.
  • Arachidonic acid is released from cell membrane phospholipids mainly by phospholipase A2.
  • the cyclooxygenase pathway produces thromboxane and prostaglandins from arachidonic acid.
  • Leukotriene B4 carries hydroxyl moiety only and binds to BLT receptors.
  • the signaling pathway via G protein-coupled BLT receptor activation produces a potent chemotaxis response.
  • Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have amino acid moiety and bind to cysteinyl leukotriene receptors (CysLTI and CysLT2). Bronchoconstriction, vascular permeability, eosinophil recruitment, and chronic inflammation are mediated through the G protein-coupled activation of cysteinyl leukotriene receptors.
  • Montelukast is the antagonist to cysteinyl leukotriene CysLTI receptors.
  • Montelukast is a leukotriene receptor antagonist and as such may be used for the treatment and prevention of leukotriene-mediated diseases and disorders.
  • Leukotriene antagonists are useful in the treatment of asthma, allergic rhinitis (including seasonal and perennial), atopic dermatitis, chronic urticaria, sinusitis, nasal polyps, chronic obstructive pulmonary disease, conjunctivitis including rhinoconjunctivitis, migraine, cystic fibrosis, and wheezing secondary to viral (such as respiratory syncytial virus) bronchiolitis, among others.
  • Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
  • LTRA leukotriene receptor antagonist
  • Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLTI in the lungs and bronchial tubes by binding to it, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation.
  • Montelukast sodium is a selective leukotriene D4 receptor antagonist, and is the active ingredient of Singulair® which has been available on the market worldwide in tablet and an oral granule formulations.
  • Singulair® is prescribed for the prophylaxis and chronic treatment of asthma, and for the relief of symptoms of seasonal and perennial allergic rhinitis.
  • the compound is disclosed in US Patent 5,565,473.
  • Montelukast is an orally dosed drug (available as a film-coated tablet, chewable tablet or oral granules) which is FDA- approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
  • DPIs offer several advantages, including enhanced drug stability, greater accuracy in dosing, elimination of hand-to-mouth coordination, and consequently, an overall improvement in patient compliance.
  • Dry powder compositions that are suitable to be used via DPI, must fulfill a number of demands. With the aim of fulfilling these demands, it would be highly advantageous to provide a formulation exhibiting good uniformity of distribution of the active ingredient, small drug dosage variation (in other words, adequate accuracy of the delivered doses), good flowability, adequate physical stability. Dry powder formulations are usually prepared by mixing the micronized drug particles with larger carriers and other suitable particles.
  • Contriving the compositions is based on containing the active ingredient along with the carrier and other suitable particles having the particle sizes capable of carrying said active ingredient to the respiratory system.
  • carrier particle size enabling conveying the active ingredient to the respiratory system in the desired levels is also critical.
  • Small drug particles are likely to agglomerate. Said coagulation can be prevented by employing suitable carrier and carrier mixtures. It also assists in controlling the fluidity of the drug coming out of the carrier device and ensuring that the active ingredient reaching to lungs is accurate and consistent.
  • the mixture of the drug particles adhered to the carrier and other suitable particles such as lubricant/glidant should be homogeneous. Adhesion should be quite strong as the drug could not detach from the carrier and other suitable particles. Moreover, lower doses of powder should also be filled into the device and the drug should always be released in the same way. Therefore, it has been found to be very important to employ the fine (small) and coarse (large) particles of the selected carrier in the compositions of the present invention in an accurate ratio.
  • Particle sizes of the selected carrier and glidant/lubricant (if needed) of a drug to be administered by inhalation and their ratio in the formulation are very important to obtain the desired FPF results.
  • the main object of the present invention is to provide a novel process for preparing dry powder inhalation compositions which eliminate all aforesaid problems and bring additional advantages to the relevant prior art.
  • Another object of the present invention is to provide a novel process for manufacturing dry powder compositions for inhalation with enhanced uniformity and homogeneity.
  • Another object of the present invention is to provide a novel process for preparing dry powder inhalation compositions with increased uniformity and homogeneity, enhanced fine particle dose (FPD) and fine particle fraction (FPF).
  • FPD fine particle dose
  • FPF fine particle fraction
  • Another object of the present invention is to obtain inhalation compositions having high homogeneity and uniformity with appropriate rotational speeds.
  • Another object of the present invention is to provide a novel process for manufacturing dry powder compositions for inhalation which eliminates the requirement of other process steps like sieving and saves time, provides one-pot manufacturing accordingly.
  • Another object of the present invention is to obtain dry powder inhalation compositions provided by the above-mentioned process comprising leukotriene receptor antagonist.
  • Another object of the present invention is to obtain inhalation compositions comprising montelukast or a pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to obtain inhalation compositions having appropriate particle size and ratios of both carriers and active agents ensuring content uniformity and dosage accuracy in each blister or capsule.
  • Another object of the present invention is to obtain inhalation compositions having appropriate particle size and ratios of both carriers and active agents ensuring that effective doses of active agents reach the alveoli.
  • a further object of the present invention is to obtain inhalation compositions which can be administered in blister pack or in capsule using an inhaler.
  • a further object of the present invention is to obtain a blister pack filled with the above- mentioned dry powder inhalation compositions.
  • a further object of the present invention is to obtain a capsule filled with the above-mentioned dry powder inhalation compositions.
  • fine particle dose and fine particle fraction values were enhanced according to different rotational speeds and timing as the forces between the active and excipient particles were effected from the operating conditions.
  • the present invention relates to a process for preparing dry powder inhalation compositions, comprising the following steps: i. plastering the inner wall of the mixing vessel with %30 by weight of the first carrier and mixing with the mixer ii. adding %50 by weight of the active agent and %50 by weight of the second carrier into the plastered mixing vessel and mixing with the mixer. iii. adding %50 by weight of the active agent and %50 by weight of the second carrier, and then %70 by weight of the first carrier respectively into the plastered mixing vessel and mixing with the mixer iv.
  • the rotational speed of the mixer in the step numbered (ii) and (iii) are 200-500 rpm, preferably 200-450 rpm, more preferably 200-400 rpm and the rotational speed in the step numbered (iv) is 100- 400 rpm, preferably 100-350 rpm, more preferably 100-300 rpm.
  • said mixer is high shear mixer.
  • said mixer further comprises a chopper with a rotation speed of 100-3000 rpm, preferably 100- 2500 rpm, more preferably 100- 2000 rpm.
  • chopper speed is open from the beginning to the end of the process.
  • plastering the inner wall of the mixing vessel with %30 by weight of the first carrier is continued for at least 3 minutes.
  • the active agent is divided into two equal portions. And active agent is added to the process separately in the step numbered (ii) and (iii) of the process that is the subject of the invention. The purpose of this is to ensure the uniformity of the dose given to the patient and reaching the lungs by ensuring its homogeneous distribution in the formulation.
  • adding %50 by weight of the active agent and %50 by weight of the second carrier into the plastered mixing vessel and mixing with the mixer is continued for at least 3 minutes.
  • the rotational speed of the mixer in the step numbered (ii) is 200-500 rpm, preferably 200-450 rpm and more preferably 200-400 rpm.
  • adding %50 by weight of the active agent and %50 by weight of the second carrier, and then %70 by weight of the first carrier respectively into the plastered mixing vessel and mixing with the mixer is continued for at least 10 minutes.
  • the rotational speed of the mixer in the step numbered (iii) is 200-500 rpm, preferably 200-450 rpm and more preferably 200-400 rpm.
  • adding lubricant/glidant into the mixing vessel and mixing with the mixer is continued for at least 3 minutes.
  • the rotational speed in the step numbered (iv) is 100- 400 rpm, preferably 100-350 rpm and more preferably 100-300 rpm.
  • the rotational speed is one of the most important aspects of the invention. It is surprisingly found that by using 200-500 rpm, preferably 200-450 rpm and more preferably 200-400 rpm in the step numbered (ii) and (iii) and by using 100- 400 rpm, preferably 100-350 rpm and more preferably 100-300 rpm in the step numbered (iv), the homogenization of the formulation powder is increased, the separation of the powder was prevented and thus a more homogeneous and stable composition is obtained. The desired quality profile was not achieved, when the inventors used same rotational speeds in the step numbered (ii), (iii) and (iv) of the process.
  • the first carrier mentioned in the step numbered (i) and (iii) are coarse carrier particles.
  • Said coarse carrier particles is selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol, maltitol or mixtures thereof.
  • said the first carrier is coarse lactose.
  • a coarse lactose such as lactose monohydrate, is applied to de-agglomerate the drug particles and optimize the deposition of the drug in the lung.
  • the particle size distribution of the carrier plays a crucial role for the qualification of the composition subjected to the invention.
  • the mean particle size (D50 value) of coarse lactose is between 25-250 pm, preferably 35-100 pm.
  • the active agent mentioned in the step numbered (ii) and (iii) is a leukotriene receptor antagonist.
  • the leukotriene receptor antagonist is selected from the group comprising montelukast, zafirlukast, zileuton asitazanolast, iralukast, pranlukast, verlukast or a pharmaceutically acceptable salt thereof.
  • said the leukotriene receptor antagonist is montelukast, preferably montelukast sodium.
  • montelukast sodium has a d90 particle size less than 15 pm, preferably less than 12 pm, more preferably less than 10 pm.
  • the second carrier mentioned in the step numbered (ii) is fine carrier particles.
  • Said fine carrier particles is selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol, maltitol or mixtures thereof.
  • said second carrier is fine lactose.
  • the mean particle size (D50 value) of fine lactose is between 0.01-25 pm, preferably 0.01-20 pm.
  • the choice of carrier is essential in ensuring that the device works correctly and delivers the right amount of active to the patient. Therefore, to use lactose as a carrier in two different particle sizes (fine and coarse) is essential.
  • Particle size distribution of the carrier plays a crucial role for the qualification of the composition subjected to the invention.
  • particle size distribution means the cumulative volume size distribution as tested by any conventionally accepted method such as the laser diffraction method (Malvern analysis).
  • Laser diffraction measures particle size distributions by measuring the angular variation in intensity of light scattered as a laser beam passes through a dispersed particulate sample. Large particles scatter light at small angles relative to the laser beam and small particles scatter light at large angles. The angular scattering intensity data is then analyzed to calculate the size of the particles responsible for creating the scattering. The particle size is reported as a volume equivalent sphere diameter.
  • the D50 value is the size in microns that splits the distribution with half above and half below this diameter.
  • said lactose monohydrate is present in the composition in two parts.
  • One of these parts is lactose monohydrate having fine particle size which means the mean particle size (D50 value) is in the range of 0.01-25 pm, preferably 0.01-20 pm.
  • the other part is lactose monohydrate having coarse particle size which means the mean particle size (D50 value) is in the range of 25-250 pm, preferably 35-100 pm.
  • Coarse carrier particles are used to carry the active agent particles having mean particle size lower than 10 pm through the airways. During inhalation, as the active agent and the carrier particles need to be separated from each other, shape and surface roughness of the carrier particles are especially important. Particles having smooth surface will be separated much easier from the active agents compared to the particles in the same size but having high porosity.
  • Active agent particles will tend to concentrate on the regions having higher energy as the surface energy does not dissipate on the coarse carrier particles evenly. This might prevent separation of the active agent particles from the coarse carrier after pulmonary administration, especially in low dose formulations. In this sense, fine carrier particles are used to help the active agents to reach to the lungs easier and in high doses. As the high- energy regions of coarse carrier particles will be covered by fine carrier particles, the active agent particles will be attaching to low energy regions; thus, the amount of active agent particles detached from the coarse carrier particles will potentially increase.
  • lubricants/glidants are selected from the group comprising magnesium stearate, sodium stearate, calcium stearate, zinc stearate, lithium stereate, sodium stearyl fumarate, silicon dioxide, talc, colloidal silicon dioxide, corn, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulfate, behenic acid, erucic acid, lauric acid, oleic acid, palmitic acid, glyceryl behenate, aluminum dioxide, starch, titanium dioxide, sodium stearoyl lactylate, dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), dipalmitoyl phosphatidylinositol
  • DPPC
  • lubricant/glidant is magnesium stearate.
  • the magnesium stearate is preferably used for this purpose in dry powder formulations.
  • some of the active sites of carrier particles are occupied by magnesium stearate and the inter particulate forces (i.e. adhesive forces and cohesive forces) are balanced in the formulation, therefore not being too weak which would lead to the falling off the drug particles and forming agglomerates and not too strong which would not enable their detachment from the carrier surface.
  • the active sites are occupied by magnesium stearate, enabling some active sites to be occupied by the drug particles and therefore aerosolize upon actuation.
  • Moisture uptake can directly affect the flowability of the powders and the force to detach the micronized particles from the carrier surface.
  • Use for magnesium stearate in the formulation of the present invention also helps to minimize the influence of penetrating moisture during the storage of said formulation and results in said formulation to be more stable against the moisture.
  • the quality of the pharmaceutical formulation remains considerably better than conventional formulations which are free of magnesium stearate even on storage under extreme conditions of temperature and humidity. Therefore, the use of magnesium stearate also improves the moisture resistance of the dry powder formulations.
  • magnesium stearate is poorly water-soluble, its presence in such amount may raise some concerns as to a potential irritation or toxicity of this excipient, part of which can be inhaled by the patient together with the active agent. Therefore, it is important to determine the optimum concentration of the magnesium stearate that enables eliminating or minimizing potential irritation or toxicity of this excipient while getting balanced inter particulate forces between montelukast particles and the carrier surface which will enable maximum aerosolization deposition and minimizing the influence of penetrating moisture during the storage of the formulation.
  • This preferred rotation speed of the process and its particle size distribution eliminates agglomeration of active agent particles and assures enhanced homogeneity, stability, moisture resistance, fluidity, content uniformity and dosage accuracy.
  • the process for preparing dry powder inhalation compositions subjected to the invention are prepared by these steps: i. plastering the inner wall of the mixing vessel with %30 by weight of coarse lactose and mixing with the mixer ii. adding %50 by weight of montelukast and %50 by weight of fine lactose into the plastered mixing vessel and mixing with the mixer iii. adding %50 by weight of montelukast and %50 by weight of fine lactose and then %70 by weight of coarse lactose into the plastered mixing vessel and mixing with the mixer iv.
  • the rotational speed of the mixer in the step numbered (ii) and (iii) are 200-500 rpm, preferably 200-450 rpm, more preferably 200-400 rpm and the rotational speed in the step numbered (iv) is 100- 400 rpm, preferably 100-350 rpm, more preferably 100-300 rpm.
  • the invention also defines dry powder inhalation compositions obtained by the process subjected to the invention.
  • the dry powder composition comprises a leukotriene receptor antagonist or a pharmaceutically acceptable salt thereof.
  • the dry powder composition comprises montelukast sodium.
  • the amount of montelukast sodium is between 0.01-50 %, preferably 0.01- 40%, more preferably 0.01- 35% by weight of the total composition.
  • the dose weight of montelukast sodium is in the range of 0.005-10 mg, preferably 0.005-8 mg, more preferably 0.005-5.
  • the amount of the fine lactose is in the range of 0- 25%, preferably 0.5 - 20%, more preferably 1-15 % by weight of the total composition.
  • the amount of coarse lactose is between 23.5-99.98%, preferably 38.6-99.48%, more preferably 48.7-98.98% by weight of the total composition.
  • the amount of the magnesium stearate is in the range of 0.01-1.5%, preferably 0.01- 1.4%, more preferably 0.01- 1.3% by weight of the total composition.
  • the process for the dry powder composition subjected to the invention comprises;
  • magnesium stearate - 0.1 -1.5% by weight of magnesium stearate
  • the below-given formulations can be used as a process for preparing dry powder inhalation compositions subjected to the invention.
  • These examples are not limiting the scope of the present invention and should be considered under the light of the foregoing detailed disclosure.
  • Example 1 Dry powder composition for inhalation
  • Example 2 Dry powder composition for inhalation
  • Example 3 Dry powder composition for inhalation
  • Example 4 Dry powder composition for inhalation Unlike processes in the art in which sieving is essential to assure stable and uniform dry powder compositions, these suggested processes don’t require any sieving step to provide such compositions.
  • the process subjected to the invention only requires a mixer defined as in any embodiment above.
  • the uniformity and FPD value are enhanced by the coordinated effect of the selected rotational speed range. As FPD and FDP values are enhanced, the accurate and consistent transport of the active agents to the lungs is guaranteed.
  • the increase in stability also leads the extension of the shelf life of the final composition.
  • the process subjected to the invention eliminates sieving procedures required labor and production cost are considerably reduced, thus an increased production output it provided.
  • the dry powder composition subjected to the invention is suitable for administration in dosage forms such as capsules, cartridges or blister packs.
  • the dry powder composition subjected is suitable for administration in a multi-dose system, more preferably in a multi-dose blister pack which has more than one blister with air and moisture barrier properties.
  • Each blister contains the same amount of active agent and carrier which is provided via content uniformity and dosage accuracy of the composition. For this invention, it is ensured by the specific selection of carriers, their amounts and their mean particle sizes.
  • a blister contains 3-30 mg dry powder composition.
  • the said blister pack is arranged to be loaded in a dry powder inhaler and the composition subjected to the invention is configured to be delivered to the lungs via the said inhaler.
  • the inhaler has the means to open the blister or capsule and to provide the respective delivery of each unit dose.
  • dry powder composition subjected to the invention is used in the treatment or the prophylaxis of COVID-19, SARS-CoV-2, SARS-CoV-2 infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a simple, rapid, cost-effective, time-saving and industrially convenient process for the preparation of dry powder pharmaceutical compositions comprising leukotriene receptor antagonist as active agent. Further, the present invention also relates to the dry powder pharmaceutical compositions administered by means of inhaler devices comprising leukotriene receptor antagonists and at least one pharmaceutically acceptable excipient.

Description

A PROCESS FOR THE PREPARATION OF DRY POWDER COMPOSITIONS FOR INHALATION
Technical Field
The invention relates to a simple, rapid, cost-effective, time-saving and industrially convenient process for the preparation of dry powder pharmaceutical compositions comprising leukotriene receptor antagonist as active agent. Further, the present invention also relates to the dry powder pharmaceutical compositions administered by means of inhaler devices comprising leukotriene receptor antagonists and at least one pharmaceutically acceptable excipient.
Background of the Invention
The main indication for leukotriene receptor antagonists is in the treatment of chronic asthma and allergic rhinitis. Leukotrienes are synthesized from arachidonic acid by the action of 5- lipoxygenase in many inflammatory cells in the airways. Arachidonic acid is released from cell membrane phospholipids mainly by phospholipase A2. The cyclooxygenase pathway produces thromboxane and prostaglandins from arachidonic acid.
There are two groups of leukotrienes: one with and the other without amino acid moieties. Leukotriene B4 carries hydroxyl moiety only and binds to BLT receptors. The signaling pathway via G protein-coupled BLT receptor activation produces a potent chemotaxis response. Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have amino acid moiety and bind to cysteinyl leukotriene receptors (CysLTI and CysLT2). Bronchoconstriction, vascular permeability, eosinophil recruitment, and chronic inflammation are mediated through the G protein-coupled activation of cysteinyl leukotriene receptors. Montelukast is the antagonist to cysteinyl leukotriene CysLTI receptors.
Montelukast is a leukotriene receptor antagonist and as such may be used for the treatment and prevention of leukotriene-mediated diseases and disorders. Leukotriene antagonists are useful in the treatment of asthma, allergic rhinitis (including seasonal and perennial), atopic dermatitis, chronic urticaria, sinusitis, nasal polyps, chronic obstructive pulmonary disease, conjunctivitis including rhinoconjunctivitis, migraine, cystic fibrosis, and wheezing secondary to viral (such as respiratory syncytial virus) bronchiolitis, among others. Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLTI in the lungs and bronchial tubes by binding to it, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation.
Montelukast sodium is a selective leukotriene D4 receptor antagonist, and is the active ingredient of Singulair® which has been available on the market worldwide in tablet and an oral granule formulations. Singulair® is prescribed for the prophylaxis and chronic treatment of asthma, and for the relief of symptoms of seasonal and perennial allergic rhinitis. The compound is disclosed in US Patent 5,565,473. Its chemical name is sodium;2-[1-[[(1R)-1-[3- [(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2yl)phenyl]propyl] sulfanylmethyl]cyclopropyl]acetate and its chemical structure is shown in Formula I.
Figure imgf000003_0001
Formula I
Montelukast is an orally dosed drug (available as a film-coated tablet, chewable tablet or oral granules) which is FDA- approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
There is a need to develop a process that will allow Montelukast to be administered at a lower dose by inhalation rather than orally in high doses, and to provide higher utilization through the lungs by using the wide surface area of the lungs. Compared to other pulmonary drug delivery systems, DPIs offer several advantages, including enhanced drug stability, greater accuracy in dosing, elimination of hand-to-mouth coordination, and consequently, an overall improvement in patient compliance.
Dry powder compositions, that are suitable to be used via DPI, must fulfill a number of demands. With the aim of fulfilling these demands, it would be highly advantageous to provide a formulation exhibiting good uniformity of distribution of the active ingredient, small drug dosage variation (in other words, adequate accuracy of the delivered doses), good flowability, adequate physical stability. Dry powder formulations are usually prepared by mixing the micronized drug particles with larger carriers and other suitable particles.
Contriving the compositions is based on containing the active ingredient along with the carrier and other suitable particles having the particle sizes capable of carrying said active ingredient to the respiratory system. On the other hand, carrier particle size enabling conveying the active ingredient to the respiratory system in the desired levels is also critical.
It is a pre-condition for the medicament to possess content uniformity, in terms of user safety and effectiveness of the treatment. The difference of the particle sizes between the carrier used is important in order to ensure content uniformity. This difference to be beyond measure hampers to achieve the desired content uniformity. Another potential problem is to be unable to achieve the dosage accuracy present in each cavity in the blister or capsule. And this is of vital importance in terms of the effectiveness of the treatment.
Small drug particles are likely to agglomerate. Said coagulation can be prevented by employing suitable carrier and carrier mixtures. It also assists in controlling the fluidity of the drug coming out of the carrier device and ensuring that the active ingredient reaching to lungs is accurate and consistent.
In addition to this, the mixture of the drug particles adhered to the carrier and other suitable particles such as lubricant/glidant should be homogeneous. Adhesion should be quite strong as the drug could not detach from the carrier and other suitable particles. Moreover, lower doses of powder should also be filled into the device and the drug should always be released in the same way. Therefore, it has been found to be very important to employ the fine (small) and coarse (large) particles of the selected carrier in the compositions of the present invention in an accurate ratio. Also, it is known that the addition of lubricant/glidant to the carrier-based dry powder compositions increases the flowability, the aerosolization efficiencies of dry powder inhaler formulations, by decreasing the drug-excipient adhesion and thus facilitating the drug detachment upon device actuation.
Particle sizes of the selected carrier and glidant/lubricant (if needed) of a drug to be administered by inhalation and their ratio in the formulation are very important to obtain the desired FPF results.
In order to meet all these requirements, the process for preparing dry powder inhalation compositions should be adapted.
Thus, there is still a need for a dry powder composition of montelukast for inhalation, which ensures fluidity, content uniformity and dosage accuracy and accordingly provides high stability at the same time.
In this invention, to overcome these problems mentioned above, the process for preparing dry powder inhalation compositions comprising montelukast is provided. Also, an inhalation composition has been developed by using standard techniques which is a simple and cost- effective method.
Objects and Brief Description of the Invention
The main object of the present invention is to provide a novel process for preparing dry powder inhalation compositions which eliminate all aforesaid problems and bring additional advantages to the relevant prior art.
Another object of the present invention is to provide a novel process for manufacturing dry powder compositions for inhalation with enhanced uniformity and homogeneity.
Another object of the present invention is to provide a novel process for preparing dry powder inhalation compositions with increased uniformity and homogeneity, enhanced fine particle dose (FPD) and fine particle fraction (FPF).
Another object of the present invention is to obtain inhalation compositions having high homogeneity and uniformity with appropriate rotational speeds. Another object of the present invention is to provide a novel process for manufacturing dry powder compositions for inhalation which eliminates the requirement of other process steps like sieving and saves time, provides one-pot manufacturing accordingly.
Another object of the present invention is to obtain dry powder inhalation compositions provided by the above-mentioned process comprising leukotriene receptor antagonist.
Another object of the present invention is to obtain inhalation compositions comprising montelukast or a pharmaceutically acceptable salt thereof.
Another object of the present invention is to obtain inhalation compositions having appropriate particle size and ratios of both carriers and active agents ensuring content uniformity and dosage accuracy in each blister or capsule.
Another object of the present invention is to obtain inhalation compositions having appropriate particle size and ratios of both carriers and active agents ensuring that effective doses of active agents reach the alveoli.
A further object of the present invention is to obtain inhalation compositions which can be administered in blister pack or in capsule using an inhaler.
A further object of the present invention is to obtain a blister pack filled with the above- mentioned dry powder inhalation compositions.
A further object of the present invention is to obtain a capsule filled with the above-mentioned dry powder inhalation compositions.
Detailed Description of Invention
In accordance with the objects outlined above, detailed features of the present invention are given herein.
There are many factors to be considered during the preparation of dry powder inhalation compositions. Both the structure of the active agent and its interaction with the excipients used in the formulation is important. For this reason, it is necessary to follow an appropriate process step according to the active agent and excipients used, to be mixed at different steps, at different rates, and at different mixing speeds. The desired quality profile is obtained by incorporating the active agent and excipient portions used in the present invention into the process at different steps, at different rates, and by using different rotational speeds. By using different rotational speeds in different process steps during the process, the homogeneity of the formulation powder was increased and its segregation was prevented. Lubricant/glidant usage also had a favorable effect that courage the flowability of the powder product in order to achieve the fine particles to reach deep into the lungs.
Also fine particle dose and fine particle fraction values were enhanced according to different rotational speeds and timing as the forces between the active and excipient particles were effected from the operating conditions.
The present invention relates to a process for preparing dry powder inhalation compositions, comprising the following steps: i. plastering the inner wall of the mixing vessel with %30 by weight of the first carrier and mixing with the mixer ii. adding %50 by weight of the active agent and %50 by weight of the second carrier into the plastered mixing vessel and mixing with the mixer. iii. adding %50 by weight of the active agent and %50 by weight of the second carrier, and then %70 by weight of the first carrier respectively into the plastered mixing vessel and mixing with the mixer iv. adding lubricant/glidant into the mixing vessel and mixing with the mixer wherein the rotational speed of the mixer in the step numbered (ii) and (iii) are 200-500 rpm, preferably 200-450 rpm, more preferably 200-400 rpm and the rotational speed in the step numbered (iv) is 100- 400 rpm, preferably 100-350 rpm, more preferably 100-300 rpm.
According to one embodiment, said mixer is high shear mixer.
According to one embodiment, said mixer further comprises a chopper with a rotation speed of 100-3000 rpm, preferably 100- 2500 rpm, more preferably 100- 2000 rpm.
According to one embodiment, chopper speed is open from the beginning to the end of the process.
According to one embodiment, plastering the inner wall of the mixing vessel with %30 by weight of the first carrier is continued for at least 3 minutes. One of the key points of the invention, the active agent is divided into two equal portions. And active agent is added to the process separately in the step numbered (ii) and (iii) of the process that is the subject of the invention. The purpose of this is to ensure the uniformity of the dose given to the patient and reaching the lungs by ensuring its homogeneous distribution in the formulation.
According to one embodiment, adding %50 by weight of the active agent and %50 by weight of the second carrier into the plastered mixing vessel and mixing with the mixer is continued for at least 3 minutes. The rotational speed of the mixer in the step numbered (ii) is 200-500 rpm, preferably 200-450 rpm and more preferably 200-400 rpm.
According to one embodiment, adding %50 by weight of the active agent and %50 by weight of the second carrier, and then %70 by weight of the first carrier respectively into the plastered mixing vessel and mixing with the mixer is continued for at least 10 minutes. The rotational speed of the mixer in the step numbered (iii) is 200-500 rpm, preferably 200-450 rpm and more preferably 200-400 rpm.
According to one embodiment, adding lubricant/glidant into the mixing vessel and mixing with the mixer is continued for at least 3 minutes. The rotational speed in the step numbered (iv) is 100- 400 rpm, preferably 100-350 rpm and more preferably 100-300 rpm.
According to the preferred embodiment, in the step numbered (ii), (iii) and (iv) of the process, the rotational speed is one of the most important aspects of the invention. It is surprisingly found that by using 200-500 rpm, preferably 200-450 rpm and more preferably 200-400 rpm in the step numbered (ii) and (iii) and by using 100- 400 rpm, preferably 100-350 rpm and more preferably 100-300 rpm in the step numbered (iv), the homogenization of the formulation powder is increased, the separation of the powder was prevented and thus a more homogeneous and stable composition is obtained. The desired quality profile was not achieved, when the inventors used same rotational speeds in the step numbered (ii), (iii) and (iv) of the process.
According to the preferred embodiment, the first carrier mentioned in the step numbered (i) and (iii) are coarse carrier particles. Said coarse carrier particles is selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol, maltitol or mixtures thereof. Most preferably, said the first carrier is coarse lactose. According to the preferred embodiment, in the step numbered (i) and (iii) of the process, a coarse lactose, such as lactose monohydrate, is applied to de-agglomerate the drug particles and optimize the deposition of the drug in the lung. The particle size distribution of the carrier plays a crucial role for the qualification of the composition subjected to the invention. The mean particle size (D50 value) of coarse lactose is between 25-250 pm, preferably 35-100 pm.
According to the preferred embodiment, the active agent mentioned in the step numbered (ii) and (iii) is a leukotriene receptor antagonist. The leukotriene receptor antagonist is selected from the group comprising montelukast, zafirlukast, zileuton asitazanolast, iralukast, pranlukast, verlukast or a pharmaceutically acceptable salt thereof.
According to this preferred embodiment, said the leukotriene receptor antagonist is montelukast, preferably montelukast sodium.
According to this preferred embodiment, montelukast sodium has a d90 particle size less than 15 pm, preferably less than 12 pm, more preferably less than 10 pm.
According to the preferred embodiment, the second carrier mentioned in the step numbered (ii) is fine carrier particles. Said fine carrier particles is selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol, maltitol or mixtures thereof. Most preferably, said second carrier is fine lactose. The mean particle size (D50 value) of fine lactose is between 0.01-25 pm, preferably 0.01-20 pm.
According to one embodiment, the choice of carrier is essential in ensuring that the device works correctly and delivers the right amount of active to the patient. Therefore, to use lactose as a carrier in two different particle sizes (fine and coarse) is essential.
Particle size distribution of the carrier plays a crucial role for the qualification of the composition subjected to the invention. As used herein, ‘particle size distribution’ means the cumulative volume size distribution as tested by any conventionally accepted method such as the laser diffraction method (Malvern analysis).
Laser diffraction measures particle size distributions by measuring the angular variation in intensity of light scattered as a laser beam passes through a dispersed particulate sample. Large particles scatter light at small angles relative to the laser beam and small particles scatter light at large angles. The angular scattering intensity data is then analyzed to calculate the size of the particles responsible for creating the scattering. The particle size is reported as a volume equivalent sphere diameter.
According to this measuring method, the D50 value is the size in microns that splits the distribution with half above and half below this diameter.
In the preferred embodiment of the invention, said lactose monohydrate is present in the composition in two parts. One of these parts is lactose monohydrate having fine particle size which means the mean particle size (D50 value) is in the range of 0.01-25 pm, preferably 0.01-20 pm. The other part is lactose monohydrate having coarse particle size which means the mean particle size (D50 value) is in the range of 25-250 pm, preferably 35-100 pm.
Coarse carrier particles are used to carry the active agent particles having mean particle size lower than 10 pm through the airways. During inhalation, as the active agent and the carrier particles need to be separated from each other, shape and surface roughness of the carrier particles are especially important. Particles having smooth surface will be separated much easier from the active agents compared to the particles in the same size but having high porosity.
Active agent particles will tend to concentrate on the regions having higher energy as the surface energy does not dissipate on the coarse carrier particles evenly. This might prevent separation of the active agent particles from the coarse carrier after pulmonary administration, especially in low dose formulations. In this sense, fine carrier particles are used to help the active agents to reach to the lungs easier and in high doses. As the high- energy regions of coarse carrier particles will be covered by fine carrier particles, the active agent particles will be attaching to low energy regions; thus, the amount of active agent particles detached from the coarse carrier particles will potentially increase.
Also, it is known that the addition of lubricant/glidant to the carrier-based dry powder formulation increases the flowability and increases the aerosolization efficiencies of dry powder inhaler formulations, by decreasing the drug-excipient adhesion and thus facilitating the drug detachment upon device actuation.
In a preferred embodiment, lubricants/glidants are selected from the group comprising magnesium stearate, sodium stearate, calcium stearate, zinc stearate, lithium stereate, sodium stearyl fumarate, silicon dioxide, talc, colloidal silicon dioxide, corn, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulfate, behenic acid, erucic acid, lauric acid, oleic acid, palmitic acid, glyceryl behenate, aluminum dioxide, starch, titanium dioxide, sodium stearoyl lactylate, dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), dipalmitoyl phosphatidylinositol (DPPI), phosphatidylglycerol (PG), lecithin, soya lecithin, laxiric acid, triglycerides, hydrogenated castor oil waxy powder, l-leucine, isoleucine, trileucine, lysine, methionine, phenylalanine, valine, aspartame, and acesulfame potassium or mixtures thereof.
According to the preferred embodiment, lubricant/glidant is magnesium stearate.
The magnesium stearate is preferably used for this purpose in dry powder formulations. When magnesium stearate is used in the dry powder formulations, some of the active sites of carrier particles are occupied by magnesium stearate and the inter particulate forces (i.e. adhesive forces and cohesive forces) are balanced in the formulation, therefore not being too weak which would lead to the falling off the drug particles and forming agglomerates and not too strong which would not enable their detachment from the carrier surface. However, only some of the active sites are occupied by magnesium stearate, enabling some active sites to be occupied by the drug particles and therefore aerosolize upon actuation.
Moisture uptake can directly affect the flowability of the powders and the force to detach the micronized particles from the carrier surface. Use for magnesium stearate in the formulation of the present invention also helps to minimize the influence of penetrating moisture during the storage of said formulation and results in said formulation to be more stable against the moisture. Thus, the quality of the pharmaceutical formulation remains considerably better than conventional formulations which are free of magnesium stearate even on storage under extreme conditions of temperature and humidity. Therefore, the use of magnesium stearate also improves the moisture resistance of the dry powder formulations.
However, magnesium stearate is poorly water-soluble, its presence in such amount may raise some concerns as to a potential irritation or toxicity of this excipient, part of which can be inhaled by the patient together with the active agent. Therefore, it is important to determine the optimum concentration of the magnesium stearate that enables eliminating or minimizing potential irritation or toxicity of this excipient while getting balanced inter particulate forces between montelukast particles and the carrier surface which will enable maximum aerosolization deposition and minimizing the influence of penetrating moisture during the storage of the formulation. In this invention, surprisingly high uniformity and homogeneity are provided by the specified rotational speeds of the mixer, by the inclusion of the active agent in the process by dividing it into two equal parts and by using lubricant in the step numbered (iv). Accordingly, homogeneity is increased which means the shelf life of the final product is extended. Besides, fine particle fraction and particle size distribution of the final powder mixture are enhanced which means the accurate and consistent transport of the active agents to the lungs is guaranteed. Stability is also enhanced according to the above enhanced parameters.
This preferred rotation speed of the process and its particle size distribution eliminates agglomeration of active agent particles and assures enhanced homogeneity, stability, moisture resistance, fluidity, content uniformity and dosage accuracy.
According to one embodiment, the process for preparing dry powder inhalation compositions subjected to the invention are prepared by these steps: i. plastering the inner wall of the mixing vessel with %30 by weight of coarse lactose and mixing with the mixer ii. adding %50 by weight of montelukast and %50 by weight of fine lactose into the plastered mixing vessel and mixing with the mixer iii. adding %50 by weight of montelukast and %50 by weight of fine lactose and then %70 by weight of coarse lactose into the plastered mixing vessel and mixing with the mixer iv. adding magnesium stearate into the mixing vessel and mixing with the mixer wherein the rotational speed of the mixer in the step numbered (ii) and (iii) are 200-500 rpm, preferably 200-450 rpm, more preferably 200-400 rpm and the rotational speed in the step numbered (iv) is 100- 400 rpm, preferably 100-350 rpm, more preferably 100-300 rpm.
The invention also defines dry powder inhalation compositions obtained by the process subjected to the invention.
According to the preferred embodiment, the dry powder composition comprises a leukotriene receptor antagonist or a pharmaceutically acceptable salt thereof.
According to a preferred embodiment, the dry powder composition comprises montelukast sodium. According to one embodiment, the amount of montelukast sodium is between 0.01-50 %, preferably 0.01- 40%, more preferably 0.01- 35% by weight of the total composition.
According to one embodiment, the dose weight of montelukast sodium is in the range of 0.005-10 mg, preferably 0.005-8 mg, more preferably 0.005-5.
According to this preferred embodiment, the amount of the fine lactose is in the range of 0- 25%, preferably 0.5 - 20%, more preferably 1-15 % by weight of the total composition.
According to one embodiment, the amount of coarse lactose is between 23.5-99.98%, preferably 38.6-99.48%, more preferably 48.7-98.98% by weight of the total composition.
According to this preferred embodiment, the amount of the magnesium stearate is in the range of 0.01-1.5%, preferably 0.01- 1.4%, more preferably 0.01- 1.3% by weight of the total composition.
According to one preferred embodiment, the process for the dry powder composition subjected to the invention comprises;
- 0.01-50 % by weight of montelukast sodium
- 23.5-99.98% by weight of coarse lactose
- 0-25% by weight of fine lactose
- 0.1 -1.5% by weight of magnesium stearate
According to all these embodiments, the below-given formulations can be used as a process for preparing dry powder inhalation compositions subjected to the invention. These examples are not limiting the scope of the present invention and should be considered under the light of the foregoing detailed disclosure.
Example 1 : Dry powder composition for inhalation
Figure imgf000013_0001
Example 2: Dry powder composition for inhalation
Figure imgf000014_0001
Example 3: Dry powder composition for inhalation
Figure imgf000014_0002
Example 4: Dry powder composition for inhalation
Figure imgf000014_0003
Unlike processes in the art in which sieving is essential to assure stable and uniform dry powder compositions, these suggested processes don’t require any sieving step to provide such compositions. The process subjected to the invention only requires a mixer defined as in any embodiment above. The uniformity and FPD value are enhanced by the coordinated effect of the selected rotational speed range. As FPD and FDP values are enhanced, the accurate and consistent transport of the active agents to the lungs is guaranteed. The increase in stability also leads the extension of the shelf life of the final composition. On the other hand, as the process subjected to the invention eliminates sieving procedures required labor and production cost are considerably reduced, thus an increased production output it provided.
The dry powder composition subjected to the invention is suitable for administration in dosage forms such as capsules, cartridges or blister packs.
In the preferred embodiment, the dry powder composition subjected is suitable for administration in a multi-dose system, more preferably in a multi-dose blister pack which has more than one blister with air and moisture barrier properties.
Each blister contains the same amount of active agent and carrier which is provided via content uniformity and dosage accuracy of the composition. For this invention, it is ensured by the specific selection of carriers, their amounts and their mean particle sizes. In a preferred embodiment, a blister contains 3-30 mg dry powder composition.
In the most preferred embodiment, the said blister pack is arranged to be loaded in a dry powder inhaler and the composition subjected to the invention is configured to be delivered to the lungs via the said inhaler. The inhaler has the means to open the blister or capsule and to provide the respective delivery of each unit dose.
According to a preferred embodiment, dry powder composition subjected to the invention is used in the treatment or the prophylaxis of COVID-19, SARS-CoV-2, SARS-CoV-2 infection.

Claims

1. A process for preparing dry powder inhalation compositions, comprising the following steps: i. plastering the inner wall of the mixing vessel with %30 by weight of the first carrier and mixing with the mixer ii. adding %50 by weight of the active agent and %50 by weight of the second carrier into the plastered mixing vessel and mixing with the mixer iii. adding %50 by weight of the active agent and %50 by weight of the second carrier, and then %70 by weight of the first carrier into the plastered mixing vessel and mixing with the mixer iv. adding lubricant/glidant into the mixing vessel and mixing with the mixer wherein the rotational speed of the mixer in the step numbered (ii) and (iii) are 200-500 rpm, preferably 200-450 rpm, more preferably 200-400 rpm and the rotational speed in the step numbered (iv) is 100- 400 rpm, preferably 100-350 rpm, more preferably 100-300 rpm.
2. The process according to claim 1 , wherein the active agent is a leukotriene receptor antagonist.
3. The process according to claim 2, wherein the leukotriene receptor antagonist is selected from the group comprising montelukast, zafirlukast, zileuton asitazanolast, iralukast, pranlukast, verlukast or a pharmaceutically acceptable salt thereof.
4. The process according to claim 3, wherein the leukotriene receptor antagonist is montelukast sodium.
5. The process according to any one of the proceeding claims wherein said montelukast sodium has a d90 particle size less than 15 pm, preferably less than 12 pm, more preferably less than 10 pm.
6. The process according to claim 1 , wherein said first carrier is the coarse carrier particles.
7. The process according to claim 6, wherein said coarse carrier particles is selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol, maltitol or mixtures thereof.
8. The process according to any one of the proceeding claims, wherein said first carrier is coarse lactose.
9. The process according to any one of the proceeding claims, wherein said the mean particle size of coarse lactose is between 25-250 pm, preferably 35-100 pm.
10. The process according to claim 1 , wherein said second carrier is the fine carrier particles.
11. The process according to claim 10, said fine carrier particles is selected from the group comprising lactose, mannitol, sorbitol, inositol, xylitol, erythritol, lactitol, maltitol or mixtures thereof.
12. The process according to any one of the proceeding claims, wherein said second carrier is fine lactose.
13. The process according to any one of the proceeding claims, wherein said the mean particle size of fine lactose is between 0.01-25 pm, preferably 0.01-20 pm.
14. The process according to any one of the proceeding claims, wherein lubricants/glidants are selected from the group comprising magnesium stearate, sodium stearate, calcium stearate, zinc stearate, lithium stereate, sodium stearyl fumarate, silicon dioxide, talc, colloidal silicon dioxide, corn, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulfate, behenic acid, erucic acid, lauric acid, oleic acid, palmitic acid, glyceryl behenate, aluminum dioxide, starch, titanium dioxide, sodium stearoyl lactylate, dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), dipalmitoyl phosphatidylinositol (DPPI), phosphatidylglycerol (PG), lecithin, soya lecithin, laxiric acid, triglycerides, hydrogenated castor oil waxy powder, l-leucine, isoleucine, trileucine, lysine, methionine, phenylalanine, valine, aspartame, and acesulfame potassium or mixtures thereof.
15. The process according to any one of the proceeding claims, wherein lubricant/glidant is magnesium stearate.
16. The process according to any one of the proceeding claims, wherein for use in the treatment or the prophylaxis of COVID-19, SARS-CoV-2, SARS-CoV-2 infection.
PCT/TR2021/051073 2021-10-20 2021-10-20 A process for the preparation of dry powder compositions for inhalation WO2023069028A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/TR2021/051073 WO2023069028A1 (en) 2021-10-20 2021-10-20 A process for the preparation of dry powder compositions for inhalation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2021/051073 WO2023069028A1 (en) 2021-10-20 2021-10-20 A process for the preparation of dry powder compositions for inhalation

Publications (1)

Publication Number Publication Date
WO2023069028A1 true WO2023069028A1 (en) 2023-04-27

Family

ID=86059561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/051073 WO2023069028A1 (en) 2021-10-20 2021-10-20 A process for the preparation of dry powder compositions for inhalation

Country Status (1)

Country Link
WO (1) WO2023069028A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056812A1 (en) * 2004-11-23 2006-06-01 Vectura Limited Dry powder inhaler formulations comprising surface-modified particles with anti- adherent additives
US20090269412A1 (en) * 2000-04-17 2009-10-29 Vectura Limited Pharmaceutical formulations for dry powder inhalers
WO2013009271A1 (en) * 2011-06-02 2013-01-17 Mahmut Bilgic New improved dry powder formulation
EP2762133A1 (en) * 2010-04-01 2014-08-06 CHIESI FARMACEUTICI S.p.A. Process for preparing carrier particles for dry powders for inhalation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269412A1 (en) * 2000-04-17 2009-10-29 Vectura Limited Pharmaceutical formulations for dry powder inhalers
WO2006056812A1 (en) * 2004-11-23 2006-06-01 Vectura Limited Dry powder inhaler formulations comprising surface-modified particles with anti- adherent additives
EP2762133A1 (en) * 2010-04-01 2014-08-06 CHIESI FARMACEUTICI S.p.A. Process for preparing carrier particles for dry powders for inhalation
WO2013009271A1 (en) * 2011-06-02 2013-01-17 Mahmut Bilgic New improved dry powder formulation

Similar Documents

Publication Publication Date Title
JP6082049B2 (en) Dry powder formulation of particles containing two or more active ingredients for the treatment of obstructive or inflammatory airway diseases
JP6004233B2 (en) Dry powder formulation containing a phosphodiesterase inhibitor
JP6348501B2 (en) Very low density lung powder
EP2104490B2 (en) Micronised particles of low-dosage strength active agents for powder formulations for inhalation
CN108289962B (en) Method for preparing dry powder formulations comprising anticholinergics, corticosteroids and beta-adrenergic agents
CN108348614B (en) Method for preparing dry powder formulations comprising anticholinergics, corticosteroids and beta-adrenergic agents
CA2871358C (en) Novel dosage form and formulation of abediterol
CA3105392A1 (en) Powdered formulations of cromolyn sodium and .alpha.-lactose
EP2398473B1 (en) 5-(2-{[6-(2, 2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2-(1H)-one for the treatment of lung function
EP2682099B1 (en) Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists
WO2023069028A1 (en) A process for the preparation of dry powder compositions for inhalation
CN110612095A (en) Method for preparing dry powder formulations comprising anticholinergics, corticosteroids and beta-adrenergic agents
KR102637303B1 (en) Method for preparing dry powder formulations containing anticholinergics, corticosteroids and beta-adrenergic drugs
WO2023128913A1 (en) A process for the preparation of dry powder compositions for inhalation
CN114514020A (en) Novel carrier particles for dry powder formulations for inhalation
WO2023128918A1 (en) A process including a feeding gas system for preparing dry powder inhalation compositions
WO2023128914A1 (en) A process for the preparation of dry powder compositions for inhalation
KR20240104225A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
KR20240105510A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21961554

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE